Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is a biotechnology company with a strong focus on developing cancer therapeutics and vaccines for infectious diseases. The positive Phase 2 results for its pumitamig drug in 1L ES-SCLC and 1L NSCLC, along with its partnerships with Bristol-Myers Squibb and Summit Therapeutics, demonstrate the company's potential for success. BioNTech's commitment to its current oncology focus, as evidenced by the founding team's departure to start a new mRNA-focused biotech, shows confidence in the company's current pipeline. However, there is a potential manufacturing risk due to the complex processes involved in producing genetically modified cellular products.

Bears say

BioNTech is facing significant risks, including negative data for several of its pipeline drugs, slower market uptake, and potential delays in regulatory approvals or commercialization of its products. The company's heavy focus on developing new oncology treatments while its key source of revenue, the COVID-19 vaccine, declines also raises concerns about its future financial performance. Additionally, potential safety and efficacy concerns with its drugs could lead to delays or failure to gain regulatory approval and could significantly impact the company's forecasts and revenue generation.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $127.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $127.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.